AGAntonina Glebovna Galeeva

Antonina Glebovna Galeeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antonina Glebovna Galeeva has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endogenous controls of amplification in the indication of infectious diseases of cattle and small ruminants

    by N. I. Кhammadov, A. I. Khamidullina, M. E. Gorbunova, G. R. Salmanova, E. Yu. Tarasova, A. G. Galeeva, M. A. Efimova

    For reliable interpretation of PCR results, it is necessary to use a series of control reactions, namely: a positive, negative and an internal control. Internal control can be of two types: exogenous, which involves adding nucleic acids to the sample being analyzed (during DNA or RNA extraction) for hybridization of primers for internal amplification control, and endogenous, where the nucleic acids for control are already present in the sample itself. This study focuses on analyzing non-species-specific genes from cattle, sheep, and goats and identifying conserved loci that can be used for internal amplification control in the detection of nucleic acids from infectious agents in cattle and small ruminants. A number of genes from cattle and small ruminants were selected for oligonucleotide design, namely: beta-galactosidase, hyaluronidase, diacylglycerol O-acyltransferase, kappa-casein, lactoferrin, neuraminidase, oxytocin, and phosphorylase kinase. Taking into account the nucleotide polymorphism of non-species-specific genes in cattle, sheep, and goats, it was possible to identify the most conserved loci of the analyzed genes for the target animals, suitable for the design of corresponding primers and probes. By comparing the nucleotide sequence differences of the entire gene and its exons for each gene, it was possible to identify the most conserved loci of the exons of two of the analyzed genes, suitable for the design of corresponding primers and probes. Aligning the nucleotide sequences for each gene revealed excessive nucleotide polymorphism across different animals when aligning the nucleotide sequence of the entire gene and its exons. However, when aligning only the exons of the analyzed genes, numerous conserved loci were observed, suitable for designing of corresponding oligonucleotides. Oligonucleotides complementary to the exons (two exons separated by an intron) of the beta-galactosidase and neuraminidase genes were proposed as internal controls for RT-PCR.

  • Open Access

    Search for immunogenic epitopes in the structure of major antigens of the Newcastle disease virus

    by T. A. Bairashev, A. G. Galeeva

    Newcastle Disease (ND) is a highly contagious viral infection of birds that causes significant economic losses in the poultry industry. Traditional whole-virion vaccines often fail to provide crossneutralizing im-munity, emphasizing the need for innovative approaches to the design of new vaccine candidates. Conducting a comprehensive bioinformatics analysis of VBN representatives is necessary to achieve such goals as the creation of new candidate vaccines with a broad spectrum of protection, including DIVA-compatible ones, increasing the specificity and sensitivity of diagnostic tools, as well as overcoming the problem of antigenic drift, which will allow for the rapid adaptation of the composition of vaccines and diagnostics in accordance with the current epizootic situation. In this study, a bioinformatic analysis of the proteomes of the major Newcastle disease virus (NDV) antigens — the F and HN proteins — was carried out to identify potential immunogenic epitopes. Using sequences of var-ious viral strains circulating in Russia and neighboring countries, deposited in the GenBank database, both B-cell and T-cell epitopes were identified. The applied prediction algorithms showed that the regions with the highest epitope density are associated with critical functional domains of the proteins involved in viral membrane fusion and host receptor recognition. The results indicate high potential immunogenicity of several identified sequences. Information on epitope local-ization and antigenicity assessment serves as a foundation for further studies aimed at developing recombinant vaccines and highly specific diagnostic tools, which are key to effective control of ND spread in bird populations. This study highlights the importance of a targeted approach to vaccine design under the condi-tions of continuous antigenic evolution of the virus.

  • Open Access

    Improving immunoprophylaxis: potential and limitations of biotechnological solutions in Newcastle disease control

    by T. A. Bairashev, A. G. Galeeva, M. A. Efimova

    Introduction . Newcastle disease continues to inflict significant economic damage on the global poultry industry, dictating the need to revise traditional vaccina tion strategies. Classical live vaccines, despite their widespread use, have a number of limitations, including interference with maternal antibodies and inability to completely prevent the field virus shedding due mismatch with current genotypes. This paper constitutes an analytical review of the current landscape of genetically engineered vaccines against Newcastle disease. It systematizes the data on key technological platforms: recombinant vector vaccines, reverse genetics-based prod ucts, as well as subunit, VLP-, and DNA-vaccines. A comparative analysis of the immunogenicity, safety, and ease of use of these platforms is conducted; particular attention is paid to the possibilities of implementing the DIVA strategy. It is demonstrated that, although vector vaccines have become the industry standard, reverse genetics technologies offer unique potential for controlling viral variability and reducing virus circulation in flocks. The conclusion substantiates the need to integrate various technological approaches to create effective disease eradication programs. Objective . Formation of an objective picture of the current state of the problem, which is necessary for determining further avenues for improving biosecurity strategies in commercial poultry farming. Materials and methods. The analytical study was conducted on the basis of domestic and foreign scientific publications on Newcastle disease immunoprophylaxis Results . The existing vaccines against Newcastle disease virus have been analyzed and reviewed. Their immunogenicity, ability to overcome maternal antibodies, compatibility with the DIVA strategy, virus shedding control, safety and ease of use have been described. Historical background is also provided. The necessity of transitioning from traditional vaccines to genetically engineered prophylactic products is substantiated. Conclusion . The development and implementation of subunit and nucleic acid vaccines are the most important evolutionary steps in the field of Newcastle disease immunoprophylaxis, thus enabling the implementation of the virus eradication strategy in poultry flocks.

  • Open Access

    Development of real-time multiplex PCR for simultaneous indication of classical swine fever and Aujeski's disease viruses

    by N. I. Кhammadov, M. E. Gorbunova, Г. Р. Сальманова, E. A. Gromova, K. V. Usoltsev, A. G. Galeeva, G. N. Spiridonov, R. I. Shangaraev

    Special attention should be paid to the development and implementation of innovative diagnostic methods when carrying out preventive measures, as well as operational actions in the event of outbreaks of classical swine fever (CSF) and Aujesky's disease (AD), which will allow timely detection and localization of infection foci. The purpose of this work was to design a multiplex RT-PCR test system for the diagnosis of classical swine fever and Aujesky's disease. Using bioinformatic analysis of the nucleotide sequences of the CSF virus and the pathogen of AD, the most promising sites for the indication of these pathogens were found – 139 pairs of nucleotides (bp) in size located in the region of the CSF virus genome and 135 bp in the region of the AD genome. Based on the variability of the nucleotide sequences of the selected regions, oligonucleotides were constructed that are suitable for indicating the desired viruses by RT-PCR in one tube using different fluorescence channels. Mono- and multiplex reactions were performed for each of the created combinations of oligonucleotides using a specially developed positive control, which is a genetic construct of plasmid DNA (5827 bp) containing markers for the detection of all detectable viruses and RNA/DNA samples obtained from pig biological material. Based on the results obtained, the amplification program and the optimal composition of the reaction RT-PCR mixture were determined. It was found that an individual fluorescent label corresponded to each biological pathogen. The sensitivity of the developed RTPCR test for the diagnosis of CSF and AD can reach 4 copies of DNA in the reaction mixture. When testing the multiplex RTPCR method using the strains "ShImyn" of the CSF virus and "Arsky" of the causative agent AD, the following result was obtained – an increase in the fluorescence signal along the ROX channel (Ct – 18.3) for CSF and along the R6G channel (Ct – 22.6) for AD. Thus, we have demonstrated the possibility of simultaneous PCR to identify the genomes of the desired pathogens.

  • Methodological aspects of recombinant substances quality control in veterinary biological product manufacturing

    by A. G. Galeeva

    The active implementation of genetic engineering technologies in the production of veterinary drugs requires a review and adaptation of existing quality assurance strategies. The aim of this work is to systematize methodological approaches to assessing the quality of substances produced using recombinant DNA technologies, taking into account current regulatory requirements. The study analyzes the regulatory framework of the Russian Federation and the Eurasian Economic Union (State Pharmacopoeia of the Russian Federation, EEC decisions), as well as international guidelines (VICH, WOAH). It also examines modern analytical and molecular biology methods used in biopharmaceuticals. The paper describes a quality control algorithm for all stages of the production cycle, from cell bank characterization to the release of purified substances. Particular attention is paid to specific aspects of recombinant product quality control: confirmation of the genetic stability of producer organisms, monitoring of plasmid copy number, and protein expression levels. Requirements for the purity of pharmaceutical substances are systematized, including monitoring the profile of related impurities and process contaminants (residual DNA, host cell proteins). A comparative analysis of methods for assessing the authenticity of pharmaceutical substances is conducted. In conclusion, it is shown that the modern quality control strategy in veterinary medicine is shifting from the use of variable ( in vivo ) methods on laboratory animals to high-precision instrumental methods of analysis. The need for an integrated approach to the standardization of control methods to ensure the safety and efficacy of recombinant vaccines is substantiated.

  • Optimizing transient transfection conditions in mammalian cell production lines for expression of classical swine fever virus E2 antigen

    by A. G. Galeeva, Y. A. Kuznetsova, A. R. Akhunova, N. I. Khammadov, K. S. Khaertynov, R. S. Mukhammadiev, M. A. Efimova

    Introduction. Despite no cases of classical swine fever (CSF) have been recorded in the Russian Federation since 2021, gaining official recognition, as a disease-free zone, will require adoption of effective, safe vaccines compatible with the DIVA strategy. A range of expression systems is being evaluated as potential platforms for a recombinant subunit vaccine; synthesizing the E2 antigen in mammalian cells appears to be a particularly promising approach. Objective. Optimizing transient transfection conditions in mammalian cell production lines for expression of classical swine fever virus (CSFV) E2 antigen. Materials and methods. The nucleotide sequence encoding a 188-amino acid fragment of the E2 antigen was cloned into the pVAX1 vector. Transient transfection was performed using two common methods – calcium-phosphate and cationic (employing branched polyethylenimine, PEI) – on three established mammalian production cell lines: CHO-K1, PK-15, and BHK-21/13. Expression efficiency was controlled using immunofluorescence, quantitative reverse transcription polymerase chain reaction, and enzyme-linked immunosorbent assay. Results. It was determined that all the cell lines evaluated underwent transfection with an efficiency ranging from 60 to 90%. Cellular viability 24 hours post-transfection was at least 87%, with the lowest rates observed following calcium-phosphate transfection using an initial 12-hour incubation period. In all cases, transfection was accompanied by expression of specific messenger RNAs. The highest yield of the 17.3 kDa recombinant E2 protein was achieved in the CHO-K1 cell line (up to 47.4 mg/L), while the lowest yield was observed in the BHK-21/13 line (up to 24.1 mg/L). The specificity ratio in the antigen variant of the indirect enzyme-linked immunosorbent assay using specific antisera ranged from 5.1 to 6.2 units for all the expressed protein variants. Conclusion. All the cell lines presented in the study demonstrated satisfactory transfection efficiency. Combined with their properties – such as high proliferation rates and adaptation to serum-free media – this makes them suitable for stable expression. Both the calcium-phosphate and cationic methods provide high transfection efficiency, relatively low cytotoxicity, and good reproducibility. The combined use of these control methods is advisable during the design phase of expression systems. In a production setting, however, the primary metric of their functionality is the overall yield of the specific recombinant protein, as determined by antigen-specific enzyme-linked immunosorbent assay.

  • Open Access

    Preparation and determination of the serological activity of recombinant brucella O-antigen synthesized in the eukaryotic expression system

    by N. I. Кhammadov, E. A. Gromova, M. E. Gorbunova, A. G. Galeeva, M. A. Kosarev, K. V. Usoltsev, M. A. Efimova

    Brucellosis is a dangerous zoonotic disease caused by bacteria of the genus Brucella . having a significant negative impact on the productivity of farm animals. In the Russian Federation, successes in the fight against this disease in cattle are associated with the use of a vaccine based on the Brucella abortus 82 strain, as well as the timely detection of infected animals. This work is devoted to the preparation and study of the serological activity of recombinant O-antigen for the indication of antibodies against brucellosis. As a result of conducting search queries in the GenBank database, we identified the amino acid sequence of the O-polysaccharide antigen brucella –WP_002967174.1. This sequence was optimized for protein translation in mammalian cell culture, synthesized, and cloned into the pVax1 plasmid. pVax1 was developed by transformation of Escherichia coli cells of the DH5a strain by heat shock, with selection for the kanamycin resistance gene with further isolation and purification of plasmid DNA. Transfection of HEK293 cells with the resulting genetic construct led to the expression of the target antigen, the presence of which in the liquid taken from the cell culture was established using vertical electrophoresis in 12% PAAG based on the visualization of major patterns at the level of 70 kDa. As a result of ion exchange and gel filtration chromatography, it was possible to obtain purified O-antigen in dissolved form at a concentration of 4.7 mg/ml. The resulting drug was used in a dilution of 10 micrograms/ml, as an antigen, during indirect solid-phase ELISA to indicate antibodies in bovine blood sera against S and R brucella antigen. The coefficient of specificity was calculated with respect to ELISA data with blood serum at a dilution of 1:256. Thus, in the reaction with bovine blood serum against Brucella abortus , the specificity coefficient was 6.29, against S and R brucella antigens – 6.1 and 6.77, respectively. The results of the study can make a significant contribution to the development of methods for the diagnosis and treatment of brucellosis, as well as to the creation of new vaccine preparations.


  • ENZYME IMMUNOASSAY TEST SYSTEM FOR INTEROPERATIVE CONTROL OF THE SPECIFICITY OF RECOMBINANT CAPSID PROTEIN OF PORCINE CIRCOVIRUS TYPE 2

    by Yuliya Aleksandrovna Kuznetsova, Alsu Ruzalevna Akhunova, Antonina Glebovna Galeeva, Kamil Saubanovich Khaertynov, Marina Anatolyevna Efimova

    Porcine circovirus infections, primarily caused by porcine circovirus type 2 (PCV2), are one of the most significant problems in global pig production. Vaccination is a key tool for control and prevention of porcine circovirus infections. Recombinant analogs of capsid protein (rCap) of porcine circovirus type 2 (PCV2) are key components of modern diagnostic test systems and subunit vaccines. The stability of its antigenic activity is a critical parameter determining the efficiency and reproducibility of the functional product. The aim of this study was to develop and test an enzyme-linked immunosorbent assay system for interoperational monitoring of the specific activity of rCap protein. To obtain recombinant analogues of the PCV-2 capsid protein, the previously constructed recombinant E. coli BL21(DE3)pLysS-ORF2 producer strain (for prokaryotic analogue) and the stably expressing Chinese hamster ovary cell line CHO-K1/PCV-ORF2 (for eukaryotic analogue) were used; protein purification was performed according to previously developed protocols. Chromatographically purified IgG isolated from a pool of sera from PCV-2-seropositive pigs was used for sensitization of the solid phase (polystyrene plates); the specific peroxidase conjugate was obtained by the periodate method. The study resulted in the production of a stable peroxidase conjugate with a labeling density of 1.5:1. The developed test system enabled semiquantitative analysis of recombinant raw materials, demonstrating good reproducibility (coefficient of variation<7%). The test system was found to be universal and capable of assessing the activity of rCap variants obtained in both prokaryotic and eukaryotic expression systems, accurately recognizing their antigenic determinants. Thus, the implementation of the semiquantitative ELISA method in the production cycle will standardize the process of in-process quality control of biomass obtained using recombinant DNA technologies and guarantee stable antigenic characteristics of vaccines and diagnostic products.

  • Isolation and purification of recombinant bovine adenovirus type 3 hexone

    by A. R. Akhunova, A. G. Galeeva, A. I. Yarullin, M. A. Efimova, D. N. Mingaleev, R. Kh. Ravilov

  • Open Access

    Design and production of recombinant multiepitope antigen to indicate antibodies against the virus arthritis-encephalitis of goats

    by N. I. Khammadov, A. G. Galeeva, M. E. Gorbunova, Г. Р. Сальманова, E. A. Gromova, A. I. Khamidullina, M. A. Efimova

    To date, the only effective means of combating goat arthritis-encephalitis viruses (CAEV) includes its early diagnosis and slaughter of all animals in dysfunctional and suspected farms, since specific preventive measures have not been developed. Among the widely available tools for diagnostic studies, PCR indication of the CAEV genome and the detection of specific antibodies of the virus can be distinguished, which directly depends on the serological activity and specificity of the antigens used in diagnostic kits. This work is devoted to the development of a recombinant antigen for serological indication of antibodies against CAEV. As a result of bioinformatic analysis, a search was performed for amino acid sequences of virus proteins, an analysis of immunogenic epitopes of these proteins, a search for N-, O-glycosylation sites, signal peptide sites and transmembrane domains. Based on the data obtained, a recombinant multiepitope antigen was designed with the following amino acid sequence "mqktnepyedfaarlleaidaepipvgaeiipesmkylrgaksqgklneeaerwrrnnppppavraytygviempenyakvcqplvqiyrtlstptyqhhhhhh». The constructed amino acid sequence, after converting it to a nucleotide one, taking into account the codon optimization of protein production in Escherichia coli, was cloned into an expression construct based on the pET28a(+) vector. As a result of the design, the length of the created plasmid for the expression of the nucleotide sequence of the CAEV was 5527 bp. The protein developed and purified by affinity chromatography, containing amino acid sequences of immunogenic epitopes of the CAEV antigens, confirmed its functionality in indirect solid-phase enzyme immunoassay using blood sera from goats with previously confirmed immune status to this virus. The recombinant multiepitope antigen presented in this paper can be widely used as an integral component in the development of diagnostic test systems.